Anti-angiogenic and Anti-inflammatory Effects of SERPINA3K on Corneal Injury

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Feb 10

PMID 21304961

Citations 31

Authors

Xiaochen Liu

Zhirong Lin

Tong Zhou

Ronrong Zong

Hui He

Zhen Liu

Jian-Xing Ma

Zuguo Liu

Yueping Zhou

Affiliations

Soon will be listed here.

Abstract

SERPINA3K is a member of the serine proteinase inhibitor (SERPIN) family. Here we evaluated the therapeutic effects of SERPINA3K on neovascularization and inflammation in a rat cornea alkali burn model that is commonly employed to study corneal wounding. Topical treatment of the injured rat cornea with SERPINA3K (20 µg/eye/day) for 7 days significantly decreased the neovascular area, compared with the groups treated with BSA or PBS. The SERPINA3K treatment also ameliorated the corneal inflammation as evaluated by the inflammatory index. Furthermore, SERPINA3K enhanced the recovery of corneal epithelium after the alkali injury. Toward the mechanism of action, SERPINA3K down-regulated the expression of the pro-angiogenic and pro-inflammatory factors, vascular endothelial growth factor and tumor necrosis factor-α and up-regulated the expression of the anti-angiogenic factor, pigment epithelium-derived factor. SERPINA3K specifically inhibited growth of vascular endothelial cells. Meanwhile, SERPINA3K significantly up-regulated the expression of EGFR in the corneal epithelium. These findings suggest that SERPINA3K has therapeutic potential for corneal inflammation and NV.

Citing Articles

Proteomic profiling of human plasma and intervertebral disc tissue reveals matrisomal, but not plasma, biomarkers of disc degeneration.

Dube C, Gilbert H, Rabbitte N, Baird P, Patel S, Herrera J Arthritis Res Ther. 2025; 27(1):28.

PMID: 39930483 PMC: 11809052. DOI: 10.1186/s13075-025-03489-9.

A novel tissue-engineered corneal epithelium based on ultra-thin amniotic membrane and mesenchymal stem cells.

Long Q, Huang C, Zhang L, Jiang H, Zhao S, Zhang L Sci Rep. 2024; 14(1):17407.

PMID: 39075142 PMC: 11286932. DOI: 10.1038/s41598-024-68219-8.

Role of Serine Protease Inhibitors A1 and A3 in Ocular Pathologies.

Kontoh-Twumasi R, Budkin S, Edupuganti N, Vashishtha A, Sharma S Invest Ophthalmol Vis Sci. 2024; 65(2):16.

PMID: 38324301 PMC: 10854419. DOI: 10.1167/iovs.65.2.16.

Exploring the Role of Polysaccharide in Corneal Injury Repair and Investigating the Relevant Mechanisms through In Vivo and In Vitro Experiments.

Liu Q, Nan Y, Yang Y, Li X, Jiang W, Jiao T Molecules. 2024; 29(1).

PMID: 38202631 PMC: 10779902. DOI: 10.3390/molecules29010049.

SerpinA3K Deficiency Reduces Oxidative Stress in Acute Kidney Injury.

Gonzalez-Soria I, Soto-Valadez A, Martinez-Rojas M, Ortega-Trejo J, Perez-Villalva R, Gamba G Int J Mol Sci. 2023; 24(9).

PMID: 37175519 PMC: 10177890. DOI: 10.3390/ijms24097815.

References

King G, Suzuma K . Pigment-epithelium-derived factor--a key coordinator of retinal neuronal and vascular functions. N Engl J Med. 2000; 342(5):349-51. DOI: 10.1056/NEJM200002033420511. View

Fornoni A, Ijaz A, Tejada T, Lenz O . Role of inflammation in diabetic nephropathy. Curr Diabetes Rev. 2008; 4(1):10-7. DOI: 10.2174/157339908783502361. View

Duh E, Gehlbach P, Ando A, Takahashi K, PEARLMAN J, Mori K . Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001; 188(2):253-63. DOI: 10.1002/jcp.1114. View

Kuo I . Corneal wound healing. Curr Opin Ophthalmol. 2004; 15(4):311-5. DOI: 10.1097/00055735-200408000-00006. View

Zhang B, Abreu J, Zhou K, Chen Y, Hu Y, Zhou T . Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci U S A. 2010; 107(15):6900-5. PMC: 2872418. DOI: 10.1073/pnas.0906764107. View

Zhou G, Chao L, Chao J . Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992; 267(36):25873-80. View

Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J . Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001; 489(2-3):270-6. DOI: 10.1016/s0014-5793(01)02110-x. View

Bressler N . Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009; 116(10 Suppl):S15-23. DOI: 10.1016/j.ophtha.2009.06.048. View

Zhang B, Hu Y, Ma J . Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. Invest Ophthalmol Vis Sci. 2009; 50(8):3943-52. DOI: 10.1167/iovs.08-2954. View

10.

Chai K, Ma J, Murray S, Chao J, Chao L . Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem. 1991; 266(24):16029-36. View

11.

Liu H, Ren J, Cooper W, Hawkins C, Cowan M, Tong P . Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A. 2004; 101(17):6605-10. PMC: 404092. DOI: 10.1073/pnas.0308342101. View

12.

Wang J, Zhang S, Mott R, Chen Y, Knapp R, Cao W . Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol. 2008; 294(5):F1166-73. DOI: 10.1152/ajprenal.00375.2007. View

13.

Michalova K, Lim L . Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008; 8(4):339-47. DOI: 10.1007/s11882-008-0054-2. View

14.

Dvorak H, Brown L, Detmar M, Dvorak A . Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146(5):1029-39. PMC: 1869291. View

15.

Yu F, Yin J, Xu K, Huang J . Growth factors and corneal epithelial wound healing. Brain Res Bull. 2009; 81(2-3):229-35. PMC: 3010187. DOI: 10.1016/j.brainresbull.2009.08.024. View

16.

Khaw P, Shah P, Elkington A . Injury to the eye. BMJ. 2004; 328(7430):36-8. PMC: 313907. DOI: 10.1136/bmj.328.7430.36. View

17.

Adamis A, Aiello L, DAmato R . Angiogenesis and ophthalmic disease. Angiogenesis. 2003; 3(1):9-14. DOI: 10.1023/a:1009071601454. View

18.

Schneider M, Wolf E . The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2008; 218(3):460-6. DOI: 10.1002/jcp.21635. View

19.

Gao G, Shao C, Zhang S, Dudley A, Fant J, Ma J . Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia. 2003; 46(5):689-98. DOI: 10.1007/s00125-003-1085-9. View

20.

Horsley M, Kahook M . Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2009; 21(2):112-7. DOI: 10.1097/ICU.0b013e3283360aad. View